HomeCompareFGMCW vs ABBV

FGMCW vs ABBV: Dividend Comparison 2026

FGMCW yields 2000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FGMCW wins by $9939315158.43M in total portfolio value
10 years
FGMCW
FGMCW
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full FGMCW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FGMCW vs ABBV

📍 FGMCW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGMCWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGMCW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGMCW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGMCW
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FGMCW beats the other by $7,691,864,773,285,735.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGMCW + ABBV for your $10,000?

FGMCW: 50%ABBV: 50%
100% ABBV50/50100% FGMCW
Portfolio after 10yr
$4969657579.32M
Annual income
$4,524,626,337,251,675.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FGMCW
No analyst data
Altman Z
-65.7
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGMCW buys
0
ABBV buys
0
No recent congressional trades found for FGMCW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGMCWABBV
Forward yield2000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$9939315158.53M$102.3K
Annual income after 10y$9,049,252,674,478,578.00$24,771.77
Total dividends collected$9876141646.27M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FGMCW vs ABBV ($10,000, DRIP)

YearFGMCW PortfolioFGMCW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$210,700$200,000.00$11,550$430.00+$199.2KFGMCW
2$4,163,767$3,938,317.76$13,472$627.96+$4.15MFGMCW
3$77,191,133$72,735,902.82$15,906$926.08+$77.18MFGMCW
4$1,342,813,676$1,260,219,163.76$19,071$1,382.55+$1342.79MFGMCW
5$21,925,333,121$20,488,522,486.99$23,302$2,095.81+$21925.31MFGMCW
6$336,109,296,351$312,649,189,912.21$29,150$3,237.93+$336109.27MFGMCW
7$4,838,913,266,619$4,479,276,319,522.88$37,536$5,121.41+$4838913.23MFGMCW
8$65,446,276,951,058$60,268,639,755,775.59$50,079$8,338.38+$65446276.90MFGMCW
9$831,834,097,245,644$761,806,580,908,011.90$69,753$14,065.80+$831834097.18MFGMCW
10$9,939,315,158,531,418$9,049,252,674,478,578.00$102,337$24,771.77+$9939315158.43MFGMCW

FGMCW vs ABBV: Complete Analysis 2026

FGMCWStock

FG Merger Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus its search for a target business in the financial services industry in North America. The company was incorporated in 2020 and is based in Itasca, Illinois. FG Merger Corp. operates as a subsidiary of FG Merger Investors LLC.

Full FGMCW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FGMCW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGMCW vs SCHDFGMCW vs JEPIFGMCW vs OFGMCW vs KOFGMCW vs MAINFGMCW vs JNJFGMCW vs MRKFGMCW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.